1. AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome

   News item 17 July 2021 Pages: 1 - 1

2. Contaminated batches of droperidol solution recalled in UK

   News item 17 July 2021 Pages: 2 - 2

3. Health Canada requests recall of CHAMPIX lots due to impurity

   News item 17 July 2021 Pages: 3 - 3

4. Myocarditis, pericarditis included in labelling for two COVID vaccines

   News item 17 July 2021 Pages: 4 - 4

5. Risk of serotonin syndrome when bupropion administered with SRIs

   News item 17 July 2021 Pages: 5 - 5

6. Anti-VEGF monoclonal antibodies: risk of hypertension in cancer patients

   Clinical study 17 July 2021 Pages: 6 - 6

7. Cardiovascular risk not increased with mirabegron

   Clinical study 17 July 2021 Pages: 7 - 7

8. Increased risk of gastric cancer with PPIs versus H2RAs

   Clinical study 17 July 2021 Pages: 8 - 8

9. Is early-onset colorectal cancer associated with antibiotic use?

   Clinical study 17 July 2021 Pages: 9 - 9

10. Meta-analysis: cutaneous irAEs with immune checkpoint inhibitors

    Clinical study 17 July 2021 Pages: 10 - 10

11. Preventability of ADRs in mental health hospitals in England

    Clinical study 17 July 2021 Pages: 11 - 11

12. Rifabutin has favourable DDI profile versus rifampicin

    Clinical study 17 July 2021 Pages: 12 - 12

13. Other adverse reaction research

    News item 17 July 2021 Pages: 13 - 13

14. Abatacept/amlodipine/omeprazole

    Case report 17 July 2021 Pages: 14 - 14

15. Acarbose/benaglutide

    Case report 17 July 2021 Pages: 15 - 15

16. Acenocoumarol

    Case report 17 July 2021 Pages: 16 - 16

17. Acenocoumarol overdose

    Case report 17 July 2021 Pages: 17 - 17

18. Acetazolamide/antiepileptic drugs

    Case report 17 July 2021 Pages: 18 - 19

19. Acetylcysteine/paracetamol

    Case report 17 July 2021 Pages: 19 - 19

20. Ad26.CoV2 S

    Case report 17 July 2021 Pages: 20 - 20

21. Adalimumab/brodalumab

    Case report 17 July 2021 Pages: 21 - 21

22. Alcohol

    Case report 17 July 2021 Pages: 22 - 22

23. Alendronic-acid

    Case report 17 July 2021 Pages: 23 - 23

24. Alpelisib

    Case report 17 July 2021 Pages: 24 - 24

25. Amiloride

    Case report 17 July 2021 Pages: 25 - 25

26. Amiodarone

    Case report 17 July 2021 Pages: 26 - 26

27. Amiodarone/lidocaine/esmolol

    Case report 17 July 2021 Pages: 27 - 27

28. Amoxicillin/piperacillin/tazobactam

    Case report 17 July 2021 Pages: 28 - 28

29. Amphotericin-b/fluconazole/rifampicin

    Case report 17 July 2021 Pages: 29 - 29

30. Amphotericin-b/terbinafine/voriconazole

    Case report 17 July 2021 Pages: 30 - 30

31. Anabolic-steroids

    Case report 17 July 2021 Pages: 31 - 31

32. Anagrelide/heparin/hydroxycarbamide

    Case report 17 July 2021 Pages: 32 - 32

33. Anakinra/dexamethasone/etoposide

    Case report 17 July 2021 Pages: 33 - 33

34. Anti-TNF-monoclonal antibodies/Disease modifying antirheumatics

    Case report 17 July 2021 Pages: 34 - 34

35. Antibacterials/antiulcers

    Case report 17 July 2021 Pages: 35 - 35

36. Antidepressants

    Case report 17 July 2021 Pages: 36 - 36

37. Antidiuretics/hydrocortisone/ifosfamide

    Case report 17 July 2021 Pages: 37 - 37

38. Antiepileptic drugs/cortisone

    Case report 17 July 2021 Pages: 38 - 38

39. Antifungals/immunosuppressants

    Case report 17 July 2021 Pages: 39 - 39

40. Antineoplastics

    Case report 17 July 2021 Pages: 40 - 40

41. Antineoplastics

    Case report 17 July 2021 Pages: 41 - 41

42. Antineoplastics

    Case report 17 July 2021 Pages: 42 - 42

43. Antineoplastics

    Case report 17 July 2021 Pages: 43 - 43

44. Antineoplastics

    Case report 17 July 2021 Pages: 44 - 44

45. Antineoplastics

    Case report 17 July 2021 Pages: 45 - 45

46. Antineoplastics

    Case report 17 July 2021 Pages: 46 - 46

47. Antineoplastics

    Case report 17 July 2021 Pages: 47 - 47

48. Antineoplastics

    Case report 17 July 2021 Pages: 48 - 48

49. Antineoplastics

    Case report 17 July 2021 Pages: 49 - 49

50. Antineoplastics

    Case report 17 July 2021 Pages: 50 - 50